Following a clinical evaluation of Ortoma's OTS™ Hip solution, Ortoma is now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan.  OTS™ Hip is a unique solution for AI-assisted orthopedic surgery of hip implants and Johnson & Johnson K.K. has obtained exclusive distribution rights for the Japanese market, for which Ortoma receives an upfront fee.

"For Ortoma, this proves that our product meets the high demands of the strategically important Japanese market. This is a significant milestone for Ortoma and we are confident that our product will create great value for surgeons and be of significant benefit to patients in need of hip replacements.", comments CEO Linus Byström.

The agreement, signed in December 2021, gives Johnson & Johnson K.K. exclusive distribution rights in Japan of Ortoma Treatment Solution for hip surgery. The agreement included a pilot period where Johnson & Johnson K.K. would evaluate the products clinically before introducing it in the Japanese market. The evaluation was conducted after Ortoma obtained the necessary regulatory approvals for the OTS™-products. The pilot period ended with good results and Ortoma receives a one-time fee for the exclusive distribution rights of OTS™ Hip in Japan. Ortoma is now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan.

Attachments

Disclaimer

Ortoma AB published this content on 24 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2023 12:46:04 UTC.